KRBP | Kiromic BioPharma, Inc.

Index- P/E- EPS (ttm)-73.73 Insider Own6.60% Shs Outstand0.98M Perf Week9.35%
Market Cap3.31M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float0.93M Perf Month-26.03%
Income-38.60M PEG- EPS next Q- Inst Own1.70% Short Float / Ratio3.67% / 0.10 Perf Quarter-35.86%
Sales- P/S- EPS this Y16.70% Inst Trans-90.07% Short Interest0.03M Perf Half Y-57.81%
Book/sh0.54 P/B5.63 EPS next Y- ROA-158.70% Target Price- Perf Year-80.13%
Cash/sh0.37 P/C8.28 EPS next 5Y- ROE-238.10% 52W Range2.59 - 22.80 Perf YTD-43.92%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-86.67% Beta-
Dividend %- Quick Ratio0.20 Sales past 5Y- Gross Margin- 52W Low17.37% ATR0.62
Employees59 Current Ratio0.20 Sales Q/Q- Oper. Margin- RSI (14)42.37 Volatility12.21% 14.44%
OptionableYes Debt/Eq0.00 EPS Q/Q-86.60% Profit Margin- Rel Volume0.23 Prev Close3.34
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume352.24K Price3.04
Recom- SMA20-16.31% SMA50-21.00% SMA200-54.29% Volume81,902 Change-8.98%
May-03-23 03:48PM
May-01-23 08:08AM
Apr-03-23 08:08AM
Mar-10-23 04:30PM
Feb-28-23 08:08AM
12:17PM Loading…
Feb-23-23 12:17PM
Feb-16-23 08:08AM
Oct-27-22 08:48AM
Oct-06-22 01:37PM
Jul-12-22 08:18AM
Jul-07-22 02:29PM
Jun-21-22 01:20PM
08:43AM Loading…
Jun-07-22 10:31AM
May-13-22 08:08AM
May-11-22 06:58AM
Apr-11-22 04:03PM
Apr-08-22 04:07PM
Apr-01-22 07:07AM
Mar-11-22 04:02PM
Feb-03-22 08:58AM
Dec-22-21 09:30AM
Nov-24-21 04:12PM
07:03AM Loading…
Oct-25-21 07:03AM
Oct-11-21 08:02AM
Oct-05-21 10:13PM
Sep-13-21 09:32AM
Aug-13-21 03:32PM
Jul-29-21 02:44PM
Jul-28-21 08:49PM
Jul-26-21 08:16PM
Jul-23-21 11:00AM
Jul-21-21 08:23PM
Jul-19-21 11:15AM
Jul-16-21 02:53PM
Jul-02-21 04:23PM
Jun-29-21 06:59PM
Jun-28-21 07:01AM
Jun-17-21 07:49AM
Jun-15-21 09:07PM
Jun-13-21 01:06PM
Jun-07-21 08:07AM
May-24-21 07:55AM
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company develops ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.